Barclays’s Revelation Biosciences REVB Stock Holding History

Barclays’s Portfolio REVB Stock Details REVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$173	Buy	+168	New	+$182	﹤0.01%	5130

Other funds holding REVB

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Barclays's REVB Position: Q2 2026 in Review

Barclays opened a new position in Revelation Biosciences (REVB) in Q2 2026: 168 shares worth $173. The stake represents ﹤0.01% of the portfolio and ranks #5130 among its holdings.

12 funds tracked by Wall St. Rank hold REVB as of Q2 2026.

Barclays held 168 shares of Revelation Biosciences worth $173 as of Q2 2026.
Revelation Biosciences was a new Barclays position in Q2 2026.
Revelation Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5130 holding.
12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.